MX2019009304A - Tratamiento para el cancer. - Google Patents

Tratamiento para el cancer.

Info

Publication number
MX2019009304A
MX2019009304A MX2019009304A MX2019009304A MX2019009304A MX 2019009304 A MX2019009304 A MX 2019009304A MX 2019009304 A MX2019009304 A MX 2019009304A MX 2019009304 A MX2019009304 A MX 2019009304A MX 2019009304 A MX2019009304 A MX 2019009304A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
erdafitinib
provides
present
Prior art date
Application number
MX2019009304A
Other languages
English (en)
Spanish (es)
Inventor
STUYCKENS Kim
Jose PEREZ RUIXO Juan
Marie Z De Porre Peter
Narayan Avadhani Anjali
LORIOT Yohann
O Siefker-Radtke Arlene
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019009304(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of MX2019009304A publication Critical patent/MX2019009304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
MX2019009304A 2017-02-06 2018-02-02 Tratamiento para el cancer. MX2019009304A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
MX2019009304A true MX2019009304A (es) 2019-09-19

Family

ID=61094531

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009304A MX2019009304A (es) 2017-02-06 2018-02-02 Tratamiento para el cancer.
MX2022007955A MX2022007955A (es) 2017-02-06 2019-08-05 Regimenes de dosificacion de erdafitinib.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022007955A MX2022007955A (es) 2017-02-06 2019-08-05 Regimenes de dosificacion de erdafitinib.

Country Status (25)

Country Link
US (2) US11077106B2 (enExample)
EP (2) EP4286005A3 (enExample)
JP (3) JP2020505425A (enExample)
KR (2) KR20190110581A (enExample)
CN (1) CN110198716A (enExample)
AU (2) AU2018216969B2 (enExample)
BR (1) BR112019016043A2 (enExample)
CA (1) CA3049737A1 (enExample)
DK (1) DK3576740T3 (enExample)
ES (1) ES2953005T3 (enExample)
FI (1) FI3576740T3 (enExample)
HR (1) HRP20230697T1 (enExample)
HU (1) HUE062453T2 (enExample)
IL (1) IL268463A (enExample)
JO (1) JOP20190190A1 (enExample)
LT (1) LT3576740T (enExample)
MX (2) MX2019009304A (enExample)
PH (1) PH12019501885A1 (enExample)
PL (1) PL3576740T3 (enExample)
RS (1) RS64778B1 (enExample)
SG (2) SG10202105110VA (enExample)
SI (1) SI3576740T1 (enExample)
SM (1) SMT202300233T1 (enExample)
TW (1) TWI874925B (enExample)
UA (1) UA126336C2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
SMT202200177T1 (it) 2014-09-26 2022-05-12 Janssen Pharmaceutica Nv Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
MA54932A (fr) * 2019-02-12 2021-12-22 Janssen Pharmaceutica Nv Traitement contre le cancer
WO2020205493A1 (en) * 2019-03-29 2020-10-08 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EP3946340A1 (en) * 2019-03-29 2022-02-09 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
AU2021220285A1 (en) * 2020-02-12 2022-10-06 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
TW202508591A (zh) * 2023-05-24 2025-03-01 比利時商健生藥品公司 癌症治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Also Published As

Publication number Publication date
PH12019501885A1 (en) 2020-06-29
EP3576740B1 (en) 2023-06-14
BR112019016043A2 (pt) 2020-03-31
CA3049737A1 (en) 2018-08-09
JOP20190190A1 (ar) 2019-08-04
DK3576740T3 (da) 2023-07-24
US20220110935A1 (en) 2022-04-14
UA126336C2 (uk) 2022-09-21
JP2020505425A (ja) 2020-02-20
HRP20230697T1 (hr) 2023-10-13
US20200022976A1 (en) 2020-01-23
HUE062453T2 (hu) 2023-11-28
JP2025024064A (ja) 2025-02-19
US11077106B2 (en) 2021-08-03
EP4286005A3 (en) 2024-03-06
ES2953005T3 (es) 2023-11-07
AU2018216969B2 (en) 2024-04-11
EP3576740A1 (en) 2019-12-11
AU2018216969A1 (en) 2019-07-25
LT3576740T (lt) 2023-08-10
SI3576740T1 (sl) 2023-10-30
SG10202105110VA (en) 2021-06-29
FI3576740T3 (fi) 2023-08-31
AU2024201871A1 (en) 2024-04-11
EP4286005A2 (en) 2023-12-06
MX2022007955A (es) 2022-07-27
PL3576740T3 (pl) 2023-09-11
JP7668777B2 (ja) 2025-04-25
KR20250069693A (ko) 2025-05-19
TW202402290A (zh) 2024-01-16
SG11201907199QA (en) 2019-09-27
JP2023022190A (ja) 2023-02-14
IL268463A (en) 2019-09-26
SMT202300233T1 (it) 2023-09-06
TWI874925B (zh) 2025-03-01
KR20190110581A (ko) 2019-09-30
CN110198716A (zh) 2019-09-03
RS64778B1 (sr) 2023-11-30

Similar Documents

Publication Publication Date Title
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
MX2019009304A (es) Tratamiento para el cancer.
ECSP17073743A (es) Moduladores de k-ras
EA201991818A1 (ru) Лечение рака
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2018003443A1 (es) Tratamientos para el cancer.
MX2018016193A (es) Métodos para el tratamiento del cáncer de ovario.
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX2016001963A (es) Metodo de seleccion.
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
SV2019005822A (es) Metodos para tratar el cáncer de próstata
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
UY36286A (es) Tratamientos médicos basados en anamorelina
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
BR112017025264A2 (pt) tratamento de prurido
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2020012964A (es) Metodos para el tratamiento de cancer de vejiga.